Development of new therapies
EACS recommendations for development of new therapies can be summarized as follows:
- Increase support to academia-initiated clinical trials (including diagnostics, drug development, radiation therapy, associated translational research, surgery and multimodal treatment).
- Encourage and support research in drug repurposing to find new applications of well-established and widely available generic medicines.
- Adopt existing and create new innovative investigator-initiated trial concepts such as Drug Rediscovery Protocol or basket studies, exploring new engagement paradigms with the pharmaceutical industry.
- Support treatment optimization research to identify the optimal dosage and duration of existing treatments, both for the benefit of patients and to guarantee the sustainability of healthcare systems.
- Improve stratification methods of patients using multi-omics, novel complex multilayer biomarkers based on systems biology models.
- Develop methodologies for predicting treatment outcomes (in silico studies).
- Stimulate development and application of new functional and molecular imaging technologies (including radiomics).
- Increase support to already-established multicentre platforms for early drug development.
- Develop new sophisticated in vitro and in vivo functional screening methods (e.g. Interspaced clustered regularly short palindromic repeats/Cas9 based in preclinical models, i.e. Patient-derived xenografts or organoids) to identify new therapeutic paradigms.
- Support the development of academic cell therapy entities (e.g. Chimeric antigen receptor T cells cell production) to boost further innovation in less toxic immunotherapy approaches.
- Promote integration of advanced computational methods (AI, machine learning) with clinical research.
- Structure implementation research in therapeutics to effectively introduce practice-changing therapies.
« Back